This is a working overview of Pharmacokinetics, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-30. Anything still debated is marked as such rather than presented as settled.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Together, the Barshop Institute's diverse portfolio of clinical trials provides a unique environment in which discoveries made in the laboratory can be translated into interventions with the potential to transform the prevention and treatment of age-related diseases. By combining internationally recognized expertise in basic biology, translational science, clinical investigation, and population health, the Institute is advancing a new paradigm of medicine that seeks not only to extend lifespan, but to maximize healthspan, resilience, and independence throughout the aging process.
== Journals == Numerous journals are dedicated to the field of proteomics and related areas. Note that journals dealing with proteins are usually more focused on structure and function while proteomics journals are more focused on the large-scale analysis of whole proteomes or at least large sets of proteins. Some relevant proteomics journals are listed below (with their publishers).
Richard Küch (1860-1915) was able to melt quartz glass - the basis for UV radiation sources - for the first time in 1890 and founded the Heraeus Quarzschmelze. He developed the first quartz lamp (sun lamp) for generating UV radiation in 1904, thus laying the foundation for this form of light therapy. Despite the dosage problems, doctors increasingly used quartz lamps in the early 20th century. Internal medicine specialists and dermatologists were among the most eager testers. After successful treatment of skin tuberculosis, internal medicine began to treat tuberculous pleurisy, glandular tuberculosis and intestinal tuberculosis. In addition, doctors tested the effect of quartz lamps on other infectious diseases such as syphilis, metabolic diseases, cardiovascular diseases, nerve pain such as sciatica, or nervous diseases such as neurasthenia and hysteria. In dermatology, fungal diseases, ulcers and wounds, psoriasis, acne, freckles and hair loss were also treated with quartz lamps, while in gynecology, abdominal diseases were treated with quartz lamps. Rejuvenation specialists used artificial high-altitude sunlight to stimulate gonadal activity and treated infertility, impotentia generandi (inability to conceive), and lack of sexual desire by irradiating the genitals. For this purpose, Philipp Keller (1891-1973) developed an erythema dosimeter with which he measured the amount of radiation not in Finsen units (UV radiation with a wavelength λ of 296.7 nm and an irradiance E of 10−5 W/m2), but in height solar units (HSE).
Peptidoglycan, murein or mucopeptide is a unique large macromolecule, a polysaccharide, consisting of sugars and amino acids that forms a mesh-like layer (sacculus) that surrounds the bacterial cytoplasmic membrane. The sugar component consists of alternating residues of β-(1,4) linked N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM). Attached to the N-acetylmuramic acid is an oligopeptide chain made of three to five amino acids. The peptide chain can be cross-linked to the peptide chain of another strand forming the 3D mesh-like layer. Peptidoglycan serves a structural role in the bacterial cell wall, giving structural strength, as well as counteracting the osmotic pressure of the cytoplasm. This repetitive linking results in a dense peptidoglycan layer which is critical for maintaining cell form and withstanding high osmotic pressures, and it is regularly replaced by peptidoglycan production. Peptidoglycan hydrolysis and synthesis are two processes that must occur in order for cells to grow and multiply, a technique carried out in three stages: clipping of current material, insertion of new material, and re-crosslinking of existing material to new material. The peptidoglycan layer is substantially thicker in gram-positive bacteria (20 to 80 nanometers) than in gram-negative bacteria (7 to 8 nanometers). Depending on pH growth conditions, the peptidoglycan forms around 40 to 90% of the cell wall's dry weight of gram-positive bacteria but only around 10% of gram-negative strains.
Sources: en.wikipedia.org
== History == Adalimumab was the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA). It is derived from phage display. Adalimumab was discovered as a result of a collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology, U.K., itself a collaboration of the government-funded Medical Research Council and three academics, which began in 1993. Initially named D2E7, it was then further manufactured at BASF Bioresearch Corporation, developed by BASF Knoll (BASF Pharma), and ultimately manufactured and marketed by Abbott Laboratories after Abbott's acquisition of BASF Pharma. On 1 January 2013, Abbott split into two companies, one retaining the Abbott name and the other named AbbVie. As a result, AbbVie took over development and marketing of Humira. The brand name Humira stands for "human monoclonal antibody in rheumatoid arthritis", and was named by one of Abbott's employees, Richard J. Karwoski, who was also responsible for leading the effort to get Humira approved by the FDA. It is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. It is constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. The drug candidate was discovered initially using CAT's phage display technology and named D2E7. The key components of the drug were found by guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen TNF.
=== Model === The rate at which wood dries depends upon a number of factors, the most important of which are the temperature, the dimensions of the wood, and the relative humidity. Simpson and Tschernitz have developed a simple model of wood drying as a function of these three variables. Although the analysis was done for red oak, the procedure may be applied to any species of wood by adjusting the constant parameters of the model. Simply put, the model assumes that the rate of change of the moisture content M with respect to time t is proportional to how far the wood sample is from its equilibrium moisture content
Baby monitor – a crib-side appliance for parents of infants that transmits the baby's sounds to a receiver carried by the parent, so they can monitor the baby while they are in other parts of the house. The wavebands used vary by region, but analog baby monitors generally transmit with low power in the 16, 9.3–49.9 or 900 MHz wavebands, and digital systems in the 2.4 GHz waveband. Many baby monitors have duplex channels so the parent can talk to the baby, and cameras to show video of the baby. Wireless microphone – a battery-powered microphone with a short-range transmitter that is handheld or worn on a person's body which transmits its sound by radio to a nearby receiver unit connected to a sound system. Wireless microphones are used by public speakers, performers, and television personalities so they can move freely without trailing a microphone cord. Traditionally, analog models transmit in FM on unused portions of the television broadcast frequencies in the VHF and UHF bands. Some models transmit on two frequency channels for diversity reception to prevent nulls from interrupting transmission as the performer moves around. While some consumer models use digital modulation in the 900 MHz, 2.4 GHz, or 6 GHz ISM bands, most professional wireless microphone and in-ear monitor (IEM) systems operate in the UHF TV band (typically 470–702 MHz). Modern developments include Wireless Multichannel Audio Systems (WMAS), which utilize wideband transmission to support high channel density within a single radio frequency carrier.
recognition site A specific motif or sequence, either of nucleotides in a nucleic acid molecule or of amino acids in a protein, that is "recognized" or identified by another protein in order to direct the protein's activity to a specific molecule or location. Recognition motifs may consist of a simple consecutive sequence within a single molecule or may involve multiple non-consecutive motifs, e.g. amino acids in separate parts of the same polypeptide which are brought into juxtaposition by the quaternary structure created during protein folding. Recognition sites often help to distinguish the nucleic acid or protein bearing the motif from other similar molecules and thereby identify it as a valid target for some biochemical activity, or to specify a locus or subregion within the larger macromolecule at which the activity is to occur. In this sense recognition sites are critical for properly localizing proteins to their biochemical targets. A protein's recognition site is often but not necessarily the same as its binding site or target site.
== Types == The structure of the nanotube is not changed if the strip is rotated by 60 degrees clockwise around A1 before applying the hypothetical reconstruction above. Such a rotation changes the corresponding pair (n,m) to the pair (−m,n+m). It follows that many possible positions of A2 relative to A1 — that is, many pairs (n,m) — correspond to the same arrangement of atoms on the nanotube. That is the case, for example, of the six pairs (1,2), (−2,3), (−3,1), (−1,−2), (2,−3), and (3,−1). In particular, the pairs (k,0) and (0,k) describe the same nanotube geometry. These redundancies can be avoided by considering only pairs (n,m) such that n > 0 and m ≥ 0; that is, where the direction of the vector w lies between those of u (inclusive) and v (exclusive). It can be verified that every nanotube has exactly one pair (n,m) that satisfies those conditions, which is called the tube's type. Conversely, for every type there is a hypothetical nanotube. In fact, two nanotubes have the same type if and only if one can be conceptually rotated and translated so as to match the other exactly. Instead of the type (n,m), the structure of a carbon nanotube can be specified by giving the length of the vector w (that is, the circumference of the nanotube), and the angle α between the directions of u and w may range from 0 (inclusive) to 60 degrees clockwise (exclusive). If the diagram is drawn with u horizontal, the latter is the tilt of the strip away from the vertical.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.